Discussion
HCV [, fatigue
The present RCT demonstrated that, compared to standard HCV treatment, integrated HCV treatment did not reduce fatigue from baseline to EOT12 among PWIDs; however, a non-significant improvement in the fatigue level was observed. The fatigue level was high in both the integrated and the standard HCV treatment groups, with substantial intraindividual variation from baseline to EOT12.To our knowledge, this was the first trial conducted in outpatient OAT clinics and CCCs to investigate the impact of integrated HCV treatment on fatigue among PWIDs. Although no significant improvement in integrated HCV treatment compared to standard treatment was found, we revealed non-significant reduction in FSS-9 scores with integrated HCV treatment. This implies that an integrated approach is at least equal to or possibly more effective than standard HCV treatment in reducing fatigue symptoms in this population. Achieving SVR representing 85% and 64% of participants in integrated and standard HCV treatments, respectively, according to the INTRO-HCV trial [The present study demonstrated that integrated HCV treatment was at least equal to relieving fatigue symptoms among PWIDs than standard HCV treatment, adjusted for achieving SVR. The results align with existing literature on this topic [The integrated and standard treatment groups demonstrated substantial intraindividual variation in fatigue levels over time. This corresponds with the results detected in another fatigue study of people infected with HCV [